LCN2 and alkaline phosphatase measurement: LCN-2 is proposed as an early biomarker of SAP, being several times higher in SAPas compared to mild AP (MAP) and showing 100% sensitivity and specificity in discriminatingSAP from MAP during first 48 hours. A significant relationship of LPN-2with fatal outcome was also shown.